Complementary/Integrative Cancer Care

Complementary/Integrative Cancer Care

Cancer is a complex disease. Therefore, a comprehensive approach should be taken in addressing all forms of cancer. At GMA, we advise our patients to consider an integrative approach to their disease. We are not oncologists but we do treat patients with cancer. Our goal is to nourish the body and help fortify the immune system so as to stimulate the body’s own natural healing responses.  In this effort, we combine the best of conventional medicine with our integrative approach to form a comprehensive system of care for the patient.

At the first visit, we try to understand the underlying factors in the patient’s journey from wellness to illness or disease. We then recommend a program that is tailored to the patient.

Our integrative approach consists of:

1.      Nutritional counseling

2.      Relaxation techniques;

3.      Meditation

4.      Infusion therapies

5.      Potent supplements

Our infusion program consists of: High dose vitamin C; Alpha lipoic acid; EDTA chelation therapy; Nutritional infusions – megavitamins; and many other intravenous infusions.

In addition to vitamin C infusions, we provide intravenous Magnesium as well as intravenous Glutathione. Magnesium infusions correct any deficiencies that may be present. It is also beneficial for muscle pain, headaches and anxiety. Glutathione is beneficial in a wide range of conditions including neurologic symptoms related to Parkinson's disease, metal and environmental toxicity, and impaired liver detoxification.

As mentioned earlier, cancer is a complex disease and therefore no one thing is often effective by itself in treating cancer. Likewise, in integrative cancer care, intravenous, high dose vitamin C (IVC)  is  not considered a "stand alone" therapy. It is one part of a comprehensive package which includes dietary, nutritional, and lifestyle changes that support wellness. IVC is used with traditional cancer treatments such as chemotherapy in some cases.

There are numerous examples of conventional cancer treatment where remission is achieved only to have recurrence of the cancer months to years later. Cancer cells are “outlaw” cells where they rebel against the laws of cell death or apostasies. They also carry out micro-metastasis, which would not be detected at the time of remission but only to bloom years later and cause recurrence of disease that oftentimes is worse than the initial disease. For these reasons, it is prudent to fortify the body and give all the advantages possible to prevent recurrence and help the patient enjoy a good quality of life


At Grace Medical, we do intravenous high dose vitamin C infusions for a variety of medical conditions, including cancer.

At Grace Medical, we do intravenous high dose vitamin C infusions for a variety of medical conditions, including cancer.

Our goal is to help those patients who are struggling with long term medical problems, who often have very limited options in terms of treatment and improved quality of life. It has been reported in the medical literature that there are many medical conditions that may benefit from Intravenous Vitamin C (IVC) therapy.

A lot has been written about the effectiveness of vitamin C in health and disease. Vitamin C is effective in maintaining health as well as in treating various disease states, including cancer. The effectiveness of this vitamin in cancer has been demonstrated more than sixty years ago by Dr. Frederick Klenner who wrote about 27 papers on vitamin C from the 1940’s through the 1970’s. Later, Dr. Linus Pauling also showed the effectiveness of this vitamin in many disease states including cancer. There have been reports stating that vitamin C is ineffective in preventing or ameliorating the ravages of disease. On the contrary, when one searches the literature, one would find that there is a mounting and impressive body of evidence showing the importance of this vitamin in many medical conditions.  More than 90 epidemiologic studies (1) have looked into the effectiveness of Vitamin C and vitamin-C rich foods in cancer prevention.


Vitamin C plays an important role in various biological functions in the body. Vitamin C is well known as an antioxidant. However, it has many other functions in the body. It is a powerful free radical scavenger and a good chelating agent of heavy metals and other environmental toxicants. Other functions of vitamin C include the synthesis of hormones, neurotransmitters and other substances in the body. It functions to boost the immune system. Its antioxidant effects are important in the functioning of the cardiovascular system. These are also important in lungs, bones and other systems in the body.


 Vitamin C exhibits anti-cancer properties in several ways:

(i)    It scavenges cancer-causing free radicals;

(ii)  It regenerates active Vitamin E in lipid membranes;

(iii)  It enhances IgA, IgG, and IgM antibody levels;

(iv)  It neutralizes cancer-causing agents like nitrites and nitrosamines

(v)   It modulates interferon synthesis

(vi)  It possesses anti-viral and anti-bacterial properties and thereby able to prevent and treat cancers of bacterial or viral origin

(vii) It increases synthesis of Prostaglandins PGE1, which is anti-inflammatory and inhibits synthesis of PGE2

(viii) It enhances lymphocytic function as well as the rapid mobilization of phagocytes

(ix)  High dose vitamin C produces hydrogen peroxide which is toxic to cancer cells but harmless to normal cells.


In the early days of vitamin C research, Dr. Klenner gave both oral and intravenous vitamin C to a wide range of patients with a myriad of medical problems from bacterial and  viral infections,  to cancer. His results were amazing. Decades later, the double Noble Laureate, Dr. Linus Pauling also studied and used vitamin C both in oral and IV forms in a variety of medical conditions. His results were equally impressive. Dr. Gladys Block of the University of California did an analysis of 90 epidemiological studies which looked at Vitamin C or vitamin-C rich foods(1). The vast majority of these studies found statistically significant protective effect. There was strong evidence for protection against cancers of the oral cavity, esophagus, stomach, and pancreas. These are particularly deadly cancers with extremely poor prognosis, especially pancreatic cancer. There was substantially positive effect against breast, cervical and rectal cancers in that analysis. Furthermore, there was strong evidence for protection against lung cancer, bladder, prostate, and colorectal cancers. This is a very impressive record for this vitamin.

Some of the controversy about the effectiveness of this vitamin comes as a result of improper dosing. It has been know that while orally administered vitamin C is effective in many conditions, intravenously administered vitamin C is much more potent. Some studies have used or looked at orally administered vitamin C and concluded that it was not effective. Orally administered vitamin C is actually very different from the IV form. Intravenously administered form has about 50 to 70 times more serum concentration of the vitamin compared to orally administered dose for dose. A big difference between orally administered vitamin C and the intravenously administered type is that there is a tight control in the amount of vitamin C that can be absorbed from the gastrointestinal tract. Hence with orally administered vitamin C, a ceiling is reached in the amount absorbed even when the maximum tolerated dose is give. IV vitamin C on the other hand, is not limited by this tight control. Furthermore, very high doses can be given intravenously to achieve therapeutic serum concentrations without any side effects.


How Does high dose Vitamin C work?

When we say high dose vitamin C we are talking about doses from 30, 40, 50 or 60 grams and above. At Grace Medical, we have doses of vitamin C up to 100 grams without untoward or side effects.

Researchers have shown that high dose intravenously administered vitamin C produces hydrogen peroxide in the body. Vitamin C is also very similar to glucose (see figures below) and cancer cells avidly take up glucose. When vitamin C is mistaken for glucose by the cancer cell and is taken up by them, it produces hydrogen peroxide which does not harm normal cells but kills cancer cells.

At Grace Medical, we do intravenous high dose vitamin C infusions for a variety of medical conditions, including cancer. We follow the Riordan protocol. (see below)

In summary, vitamin C is effective in preventing common infections to life threatening cancer. Oral supplementation is effective for health maintenance. However, if one has a serious challenge to one's health, something like cancer and severe autoimmune disease or infection, then intravenous vitamin C should be a major component in ones treatment regimen. At Grace Medical Association, we do IV vitamin C for a wide range of medical conditions.


  1. Agus, D., Vera, J. & Golde, D., 1999. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res., Volume 59, pp. 4555-8.
  2. Ashino, H. et al., 2003. Novel function of ascorbic acid as an angiostatic factor. Angiogenesis, Volume 6, pp. 259-69.
  3. Belin, S. et al., 2009. Antiproliferative effect of ascorbic acid is associated with inhibition of genes necessary to cell cycle progression. PLoS ONE, Volume 4, p. e4409.
  4. Benade, L., Howard, T. & Burk, D., 1969. Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1,2,4-triazole. Oncology, Volume 23, pp. 33-43.
  5. Berlin, S. et al., 2009. Antiproliferative effect of ascorbic acid is associated with inhibition of genes necessary for cell cycle progression. PLoS ONE, Volume 4, pp. E44-0.
  6. Block, Gladys: Epidemiologic evidences regarding vitamin C and Cancer Am J. Clin. Nutr 1991;54:1310S-1314S.
  7. Block, K. et al., 2008. Impact of antioxidant supplementaion on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer, Volume 123, pp. 1227-39.
  8. Cameron, E. & Pauling, L., 1976. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. PNAS USA, Volume 73, pp. 3685-9.
  9. Cameron, E., Pauling, L. & Leibovitz, B., 1979. Ascorbic acid and cancer, a review. Cancer Res, Volume 39, pp. 663-81.
  10. Campbell, A. & Jack, T., 1979. Acute reactions to mega ascorbic acid therapy in malignant disease. Scott Med J, Volume 24, p. 151.
  11. Campbell, G., Steinberg, M. & Bower, J., 1975. Letter: ascorbic acid induced hemolysis in a G-6-PD deficiency.. Ann Intern Med, Volume 82, p. 810.
  12. Casciari, J., Riordan, H., Miranda-Massari, J. & Gonzalez, M., 2005. Effects of high dose of ascorbate administration on L-10 tumor growth in guinea pigs. PRHSJ, Volume 24, pp. 145-50.
  13. Casciari, J., Riordan, N. S. T. M. X., Jackson, J. & Riordan, H., 2001. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. Br. J. Cancer, Volume 84, pp. 1544-50.
  14. Chen, Q. et al., 2008. Pharmaologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. PNAS USA, Volume 105, pp. 11105-9.
  15. Chen, Q. et al., 2005. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. PNAS USA, Volume 205, pp. 13604-13609.
  16. Chen, P., Yu, J., Chalmers, B., Drisko, J., Yang, J., Li, B., & Chen, Q. (2012). Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy. Anti-Cancer Drugs, 23(4), 437-44. doi:10.1097/CAD.0b013e32834fd01f
  17. Creagan, E. et al., 1979. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: A controlled trial. NEJM, Volume 301, pp. 687-690.
  18. Cullen, J. J. (2013). Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemotherapy and Pharmacology, 71(3), 765-75. doi:10.1007/s00280-013-2070-8
  19. Drisko, J., Chapman, J. & Hunter, V., 2003. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. Am J Coll Nutr, Volume 22, pp. 118-23.
  20. Du, J. et al., 2010. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res, Volume 16, pp. 509-20.
  21. Espey, M. et al., 2011. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med, Volume 50, pp. 1610-19.
  22. Espey, M., Chen, Q. & Levine, M., 2009. Comment re: vitamin C antagonizes the cytotoxic effects of chemotherapy. Cancer Research , Volume 69, p. 8830.
  23. Frei, B. & Lawson, S., 2008. Vitamin C and cancer revisited. PNAC USA, Volume 105, pp. 11037-8.
  24. Fritz, H., Flower, G., Weeks, L., Cooley, K., Callachan, M., McGowan, J., ... Seely, D. (2014). Intravenous Vitamin C and Cancer: A Systematic Review. Integrative Cancer Therapies, 13(4), 280-300. doi:10.1177/1534735414534463 
  25. Fromberg, A. et al., 2011. Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells toward cytostatic drugs.. Cancer Chemother Pharmacol, Volume 67, pp. 1157-66.
  26. Fujita, K. et al., 1982. Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs. Cancer Res, Volume 309-16, p. 42.
  27. Geeraert, L., 2012. CAM-Cancer Consortium. Intravenous high-dose vitamin C. [Online] Available at:
  28. Ginter, E., Bobeck, P. & Vargova, D., 1979. Tissue levels and optimal dosage of vitamin C in guinea pigs.. Nutr Metab, Volume 27, pp. 217-26.
  29. Gonzalez, M. et al., 2002. Inhibition of human breast cancer carcinoma cell proliferation by ascorbate and copper.. PRHSJ, Volume 21, pp. 21-3.
  30. Heaney, M. et al., 2008. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res., Volume 68, pp. 8031-8.
  31. Henson, D., Block, G. & Levine, M., 1991. Ascorbic acid: biological functions and relation to cancer. JNCI, Volume 83, pp. 547-50.
  32. Hoffer, L. et al., 208. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol, Volume 1969-74, p. 19.
  33. Hoffman, F., 1985. Micronutrient requirements of cancer patients.. Cancer, 55(Supl. 1), pp. 145-50.
  34. Hornig, D., 1975. Distribution of ascorbic acid metabolites and analogues in man and animals. Ann NY Acad Sci, Volume 258, pp. 103-18.
  35. Jackson, J. & Hunninghake, R., 2006. False positive blood glucose readings after high-dose intravenous vitamin C. J Ortho Med, Volume 21, pp. 188-90.
  36. Jackson, J., Riordan, H., Hunninghauke, R. & Riordan, N., 1995. High dose intravenous vitamin C and long time survival of a patient with cancer of the head and pancreas. J Ortho Med, Volume 10, pp. 87-8.
  37. Keith, M. & Pelletier, O., 1974. Ascorbic acid concentrations in leukocytes and selected organs of guinea pigs in response to increasing ascorbic acid intake. Am J Clin Nutr, Volume 27, pp. 368-72.
  38. Kuether, C., Telford, I. & Roe, J., 1988. The relation of the blood level of ascorbic acid to tissue concentrations of this vitamin and the histology of the incisor teeth in the guinea pig. J Nutrition, Volume 28, pp. 347-58.
  39. Kurbacher, C. et al., 1996. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett, Volume 103, pp. 183-9.
  40. Levine, M. et al., 1996. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. PNAS USA, Volume 93, pp. 3704-9.
  41. Lin, A., Chen, K., Chung, H. & Chang, S., 2010. The significance of plasma c-reactive protein in patients with elevated serum prostate-specific antigen levels. Urological Sci, Volume 21, pp. 88-92.
  42. Ma, Y., Chapman, J., Levine, M., Polireddy, K., Drisko, J., & Chen, Q. (2014). High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Science Translational Medicine, 6(222), 222ra18. doi:10.1126/scitranslmed.3007154
  43. Mayland, C., Bennett, M. & Allan, K., 2005. Vitamin C deficiency in cancer patients. Palliat Med, Volume 19, pp. 17-20.
  44. McCormick, W., 1959. Cancer: a collagen disease, secondary to nutrition deficiency. Arch. Pediatr., Volume 76, pp. 166-171.
  45. Mikirova, N., Casciari, J. & Riordan, N., 2012. Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo. J Angiogenesis Res, Volume 2, pp. 2-6.
  46. Mikirova, N., Casciari, J., Taylor, P. & Rogers, A., 2012. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Trans Med, Volume 10, pp. 189-99.
  47. Mikirova, N., Ichim, T. & Riordan, N., 2008. Anti-angiogenic effect of high doses of ascorbic acid.. J Transl Med, Volume 6, p. 50.
  48. Mikirova, N., Rogers, A., Casciari, J. & Taylor, P., 2012. Effects of high dose intravenous ascorbic acid on the level of inflammation in patients with rheumatoid arthritis. Mod Res Inflamm, Volume 1, pp. 26-32.
  49. Moertel, C. et al., 1985. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have no prior chemotherapy: a randomized double-blind comparison.. NEJM, Volume 312, pp. 137-41.
  50. Monti, D. et al., 2012. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One, Volume 7, p. e29794.
  51. Murata, A., Morishige, F. & Yamaguchi, H., 1982. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Res Suppl, Volume 23, pp. 103-13.
  52. OHNO, S., OHNO, Y., & SUZUKI, N. (2009). High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer ..., 29(3), 809-15. Retrieved from 
  53. Okunieff, P. & Suit, H., 1987. Toxicity, radiation sensitivity modification, and combined drug effects of ascorbic acid with misonidazole in vivo on FSaII murine firbosarcomas. JNCI, Volume 79, pp. 377-81.
  54. Padayatti, S. et al., 2006. Intravenous vitamin C as a cancer therapy: three cases. CMAJ, Volume 174, pp. 937-42.
  55. Padayatty, S. & Levine, M., 2000. Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J Am Coll Nutr., Volume 19, pp. 423-5.
  56. Padayatty, S. et al., 2010. Vitamin C: intravenous use by complementary and alternative medical practitioners and adverse effects. PLoS ONE, Volume 5, p. 11414.
  57. Padayatty, S. et al., 2004. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann. Intern. Med., Volume 140, pp. 533-37.
  58. Page, E. et al., 2007. Hypoxia incudible factor-1 (alpha) stabilization in nonhypoxic conditions: role of oxidation and intracellualr ascorbate depletion. Mol Biol Cell, Volume 19, pp. 86-94.
  59. Pollard, H., Levine, M., Eidelman, O. & Pollard, M., 2010. Pharmacological ascorbic acid supresses syngenic tumor growth and metastases in hormone-refractory prostate cancer. In VIvo, Volume 2012, pp. 249-55.
  60. Raloff, J., 2000. Antioxidants may help cancers thrive. Science News, Volume 157, p. 5.
  61. Riordan, H. et al., 2005. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. PR Health Sci J, Volume 24, pp. 269-76.
  62. Riordan, H. et al., 2003. Intravenous ascorbic acid: protocol for its application and use. PR Health Sci. J., Volume 22, pp. 225-32.
  63. Riordan, H., Jackson, J., Riordan, N. & Schultz, M., 1998. High-dose intravenous vitamin C in the treatment of a patient with renal cell carcinoma of the kidney. J Ortho Med, Volume 13, pp. 72-3.
  64. Riordan, N., JA, J. & Riordan, H., 1996. Intravenous vitamin C in a terminal cancer patient. J Ortho Med, Volume 11, pp. 80-2.
  65. Riordan, H. D., Riordan, N. H., Jackson, J. A., Casciari, J. J., Hunninghake, R., ... Rivera, A. (2004). Intravenously administered vitamin C as chemotherapy agent: a report on clinical cases. Puerto Rico Health Sciences Journal, 23(2), 115-8. Retrieved from
  66. Riordan, N., Roirdan, H. & Meng, X., 1995. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses, Volume 44, pp. 207-13.
  67. Rivers, J., 1987. Safety of high-level vitamin C ingestion. In: Third Conference on Ascorbic Acid. Ann NY Acad Sci, Volume 489, pp. 95-102.
  68. Shinozaki, K. et al., 2011. Ascorbic acid enhances radiation-induced apoptosis in an HL60 human leukemia cell line. J Ratiat Res, Volume 52, pp. 229-37.
  69. Simone, C., Simone, N. S. V. & CB, S., 2007. Antioxidants and other nutrients do not inferfere with chemotherapy or radiation therapy and can increase survival, part 1. Atlern Ther Health Med, Volume 13, pp. 22-8.
  70. St. Sauver, J. et al., 2009. Associations betweeen c-reactive protein and benigh prosaic hyperplasia lower urinary tract outcomes in a population based cohort. Am J Epidemiol, Volume 169, pp. 1281-90.
  71. Taper, H., Keyeux, A. & Roberfroid, M., 1996. Potentiation of radiotherapy by nontoxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. Anticancer Res, Volume 16, pp. 499-503.
  72. Verrax, J. et al., 2004. Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic capsase-3 independent form of cell death. Apoptosis, Volume 9, pp. 223-33.
  73. Verrax, J., & Calderon, P. B. (2009). Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radical Biology & Medicine, 47(1), 32-40. Retrieved from               
  74. Verrax, J. & Calderon, P., 2009. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med, Volume 47, pp. 32-40.
  75. Vollbracht, C. et al., 2011. Intravenous vitamin C administration improves quality of life in breast cacner patients during chemo-radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo, Volume 82, pp. 983-90.
  76. Wong, K. et al., 1994. Acute oxalate nephropathy after a massive intravenous dose of vitamin C. Aust ZN J Med, Volume 24, pp. 410-1.
  77. Yeom, C., Jung, G. & Song, K., 2007. Changes of terminal cancer patietns health related qualtiy of life after high dose vitamin C administration. Korean Med Sci, Volume 22, pp. 7-11.
  78. Yeom, C. et al., 2009. High-dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med, Volume 7, p. 70.

More on Vitamin C

The Nobel prize-winning scientist Dr. Linus Pauling was among the first to recognize the importance of high-dose vitamin C supplementation more than 30 years ago. Since then, scientists have amassed impressive evidence supporting the numerous benefits of high-dose vitamin C.

Dr. Linus Pauling noted that vitamin C is a critically important water-soluble antioxidant, as it protects proteins and lipids from free radical damage associated with infection, intensive exercise, and other stressors that can injure cells. These very properties make vitamin C a valuable agent for improving immune function. By suppressing oxidative stress, vitamin C increases the life span of immune cells and reduces infection-related cellular damage. This bolsters the immune system’s ability to fend off a broad range of infectious agents.

Interestingly, research has clearly demonstrated that during times of infection, concentrations of vitamin C are rapidly depleted in the blood and in white blood cells. Scientists have found that supplementation with vitamin C improves several important parameters of immune function. Therefore, supplementing with vitamin C during infection may protect immune cells and strengthen their ability to fight infectious pathogens.

Vitamin C Helps Prevent and Fight Infections

Vitamin C not only speeds recovery from infections, but more important, may also help to prevent the onset of infections. Study after study has shown that vitamin C can dramatically reduce infection time as well as boost one’s resistance to infections. For example, studies of vitamin C supplementation in military personnel and other subjects living in close quarters have shown that pneumonia occurred a remarkable 80-100% less often in subjects taking vitamin C than in those who did not supplement with the vitamin.

High Dose Vitamin C IV Therapy involves the intravenous infusion of high doses of vitamin C (ascorbic acid). The initial dose may be 15 or 25 grams and, if this is well tolerated, which is almost always the case, the dose is increased to 50 grams. In some cases the dose may be increased to 75 or 100 grams, or more. It can resolve both acute and chronic bacterial and viral infections, neutralize a wide variety of toxic substances and is a very safe and effective detoxifier of heavy metals. Recently, High Dose Vitamin C IV Therapy has been proven to improve outcomes for cancer patients.

An enormous amount of scientific literature on vitamin C has been written over the past century, much of it from the most esteemed research Clinics. According to Thomas E. Levy, M.D., J.D, in his excellent book Vitamin C, Infectious Diseases & Toxins, “there are very few human diseases or medical conditions that are not improved to at least some degree by the regular dosing of optimal amounts of vitamin C. There is only rarely a good reason for not immediately giving any patient large doses of vitamin C…” He continues. “Ultimately, it should become apparent to the reader that Vitamin C is the single most important nutrient substance for the body…” and “the scientific literature… clearly shows the vast clinical superiority of intravenous vitamin C over any other form of vitamin C administration. Often a significantly smaller dose of intravenous vitamin C, compared to an oral administration, will promptly result in the clinical resolution of an infectious disease.”

A recent study conducted by the National Institutes of Health (NIH) found that high concentrations of vitamin C had anticancer effects in 75 percent of the tested cancer cell lines. Non-cancerous cells were unaffected. Tumor weight was reduced by 41-53 percent in animals with advanced cancer.